Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose and an Open-Label Fixed-Dose Study in Patients With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RGLS8429

NCT05521191 is registered in ClinicalTrials.gov with Regulus Therapeutics Inc. as lead sponsor.

NCT NCT05521191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05521191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose and an Open-Label Fixed-Dose Study in Patients With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RGLS8429
Lead sponsor
Regulus Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 6, 2022
Completion date
March 27, 2025
Enrollment
68 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

adpkd, autosomal dominant polycystic kidney disease, polycystic kidney, autosomal dominant